- Patent Title: Antagonist of the fibroblast growth factor receptor 3 (FGFR3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of FGFR3
-
Application No.: US14844041Application Date: 2015-09-03
-
Publication No.: US09931341B2Publication Date: 2018-04-03
- Inventor: Laurence Legeai-Mallet , Arnold Munnich , Patricia Busca , Florent Barbault
- Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , UNIVERSITE PARIS DESCARTES , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS , UNIVERSITE PARIS DIDEROT—PARIS 7 , IMAGINE
- Applicant Address: FR Paris FR Paris FR Paris FR Paris FR Paris FR Paris
- Assignee: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM),UNIVERSITE PARIS DESCARTES,CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS),ASSITANCE PUBLIQUE HOPITAUX DE PARIS,UNIVERSITE PARIS DIDEROT-PARIS 7,IMAGINE
- Current Assignee: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM),UNIVERSITE PARIS DESCARTES,CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS),ASSITANCE PUBLIQUE HOPITAUX DE PARIS,UNIVERSITE PARIS DIDEROT-PARIS 7,IMAGINE
- Current Assignee Address: FR Paris FR Paris FR Paris FR Paris FR Paris FR Paris
- Agency: Whitham, Curtis & Cook
- Priority: WOPCT/IB2011/003254 20111212
- Main IPC: A61K31/497
- IPC: A61K31/497 ; A61K31/506 ; C08J5/18 ; C08L51/04 ; B32B27/30 ; B29C47/00 ; B29K25/00 ; B29K35/00 ; B29K201/00 ; B29L31/00 ; C08L25/06
Abstract:
The present invention relates to the treatment or prevention of skeletal disorders, in particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant of FGFR3.
Public/Granted literature
Information query
IPC分类:
